{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:45:41Z","timestamp":1792521941749,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"am","delay-in-days":291,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.autrev.2022.103056","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T20:35:37Z","timestamp":1643747737000},"page":"103056","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":160,"title":["Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease"],"prefix":"10.1016","volume":"21","author":[{"given":"Mitsuhiro","family":"Akiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2022.103056_bb0005","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet."},{"key":"10.1016\/j.autrev.2022.103056_bb0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103056_bb0015","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41590-019-0378-1","article-title":"Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry","volume":"20","author":"Zhang","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2022.103056_bb0020","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.cmet.2020.10.025","article-title":"Succinyl-CoA ligase deficiency in pro-inflammatory and tissue-invasive T cells","volume":"32","author":"Wu","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.autrev.2022.103056_bb0025","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1183\/09031936.00092309","article-title":"Usual interstitial pneumonia in rheumatoid arthritis- associated interstitial lung disease","volume":"35","author":"Kim","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2022.103056_bb0030","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1183\/09031936.00019210","article-title":"Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome","volume":"37","author":"Tsuchiya","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2022.103056_bb0035","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1801562","article-title":"MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease","volume":"379","author":"Juge","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2022.103056_bb0040","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/annrheumdis-2020-217256","article-title":"Association of the RPA3-UMAD1 locus with interstitial lung diseases complicated with rheumatoid arthritis in Japanese","volume":"79","author":"Shirai","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103056_bb0045","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41576-019-0099-1","article-title":"Telomeres and telomerase: three decades of progress","volume":"20","author":"Shay","year":"2019","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.autrev.2022.103056_bb0050","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1136\/ard.2007.075192","article-title":"Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells","volume":"67","author":"Makrygiannakis","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103056_bb0055","first-page":"405","article-title":"Smoking is associated with increased levels of extracellular peptidylarginine deiminase 2 (PAD2) in the lungs","volume":"33","author":"Damgaard","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2022.103056_bb0060","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41584-018-0070-0","article-title":"Rheumatoid arthritis and the mucosal origins hypothesis: protection turns to destruction","volume":"14","author":"Holers","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2022.103056_bb0065","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.3389\/fimmu.2020.01108","article-title":"Infectious triggers in periodontitis and the gut in rheumatoid arthritis (RA): a complex story about association and causality","volume":"11","author":"M\u00f6ller","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2022.103056_bb0070","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40168-016-0206-x","article-title":"The lung microbiota in early rheumatoid arthritis and autoimmunity","volume":"4","author":"Scher","year":"2016","journal-title":"Microbiome."},{"key":"10.1016\/j.autrev.2022.103056_bb0075","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1007\/s10067-019-04760-6","article-title":"Assessment of interstitial lung disease among black rheumatoid arthritis patients","volume":"38","author":"McFarlane","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2022.103056_bb0080","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s10067-020-05400-0","article-title":"Bidirectional association between GERD and rheumatoid arthritis: two longitudinal follow-up studies using a national sample cohort","volume":"40","author":"Kim","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2022.103056_bb0085","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016667","article-title":"The association between gastro-oesophageal reflux disease and subsequent rheumatoid arthritis occurrence: a nested case-control study from Taiwan","volume":"7","author":"Lin","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.autrev.2022.103056_bb0090","first-page":"2102149","article-title":"Fine particles matter components and interstitial lung disease in rheumatoid arthritis","author":"Zhao","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2022.103056_bb0095","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/art.40574","article-title":"The lung in rheumatoid arthritis: focus on interstitial lung disease","volume":"70","author":"Spagnolo","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2022.103056_bb0100","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1136\/annrheumdis-2015-208216","article-title":"Signs of immune activation and local inflammation are present in the bronchial tissue of patients with untreated early rheumatoid arthritis","volume":"75","author":"Reynisdottir","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103056_bb0105","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1172\/JCI28756","article-title":"Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis","volume":"116","author":"Rangel-Moreno","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2022.103056_bb0110","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/art.21758","article-title":"Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia","volume":"54","author":"Atkins","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2022.103056_bb0115","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.4049\/jimmunol.1801135","article-title":"Friend or foe: the protective and pathological roles of inducible bronchus-associated lymphoid tissue in pulmonary diseases","volume":"202","author":"Marin","year":"2019","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2022.103056_bb0120","doi-asserted-by":"crossref","first-page":"E2842","DOI":"10.1073\/pnas.1512600113","article-title":"Thy1+IL-7+ lymphatic endothelial cells in iBALT provide a survival niche for memory T-helper cells in allergic airway inflammation","volume":"113","author":"Shinoda","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2022.103056_bb0125","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20210790","article-title":"Characterization of human FDCs reveals regulation of T cells and antigen presentation to B cells","volume":"218","author":"Heesters","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2022.103056_bb0130","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.1093\/rheumatology\/keab687","article-title":"Comment on: persistence of circulating T-follicular helper cells after rituximab is associated with relapse of IgG4-related disease","volume":"60","author":"Akiyama","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2022.103056_bb0135","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/art.20765","article-title":"Increased CD4+ T cell infiltrates in rheumatoid arthritis-associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis","volume":"52","author":"Turesson","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2022.103056_bb0140","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/art.38201","article-title":"Structural changes and antibody enrichment in the lungs are early features of anti-citrullinated protein antibody-positive rheumatoid arthritis","volume":"66","author":"Reynisdottir","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2022.103056_bb0145","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005580","article-title":"NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis","volume":"5","author":"Khandpur","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2022.103056_bb0150","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/path.4359","article-title":"Neutrophil extracellular traps promote differentiation and function of fibroblasts","volume":"233","author":"Chrysanthopoulou","year":"2014","journal-title":"J Pathol"},{"key":"10.1016\/j.autrev.2022.103056_bb0155","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1093\/rheumatology\/keaa608","article-title":"Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: clinical features and prognosis","volume":"60","author":"Izuka","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2022.103056_bb0160","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1080\/14397595.2019.1621462","article-title":"Related factors, increased mortality and causes of death in patients with rheumatoid arthritis-associated interstitial lung disease","volume":"30","author":"Kakutani","year":"2020","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2022.103056_bb0165","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41584-019-0275-x","article-title":"Mechanisms of lung disease development in rheumatoid arthritis","volume":"15","author":"Wang","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2022.103056_bb0170","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00296-016-3478-3","article-title":"Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study","volume":"36","author":"Akiyama","year":"2016","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2022.103056_bb0175","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.40904","article-title":"Rheumatoid arthritis disease activity predicting incident clinically apparent rheumatoid arthritis-associated interstitial lung disease: a prospective cohort study","volume":"71","author":"Sparks","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2022.103056_bb0180","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.27405","article-title":"Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study","volume":"62","author":"Bongartz","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2022.103056_bb0185","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1136\/annrheumdis-2017-211138","article-title":"A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality","volume":"76","author":"Hyldgaard","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103056_bb0190","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.3390\/jcm10173806","article-title":"Decision-making strategy for the treatment of rheumatoid arthritis-associated interstitial lung disease (RA-ILD)","volume":"10","author":"Yamakawa","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.autrev.2022.103056_bb0195","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1164\/rccm.200703-463PP","article-title":"Acute exacerbations of idiopathic pulmonary fibrosis","volume":"176","author":"Collard","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2022.103056_bb0200","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003132","article-title":"Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study","volume":"3","author":"Hozumi","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.autrev.2022.103056_bb0205","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2022.103056_bb0210","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.39971","article-title":"Progressive decline of lung function in rheumatoid arthritis-associated interstitial lung disease","volume":"69","author":"Zamora-Legoff","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2022.103056_bb0215","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3390\/jcm10040874","article-title":"Predictors of progression and mortality in patients with prevalent rheumatoid arthritis and interstitial lung disease: a prospective cohort study","volume":"10","author":"Mena-V\u00e1zquez","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.autrev.2022.103056_bb0220","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1159\/000502551","article-title":"Rheumatoid arthritis-associated interstitial lung disease: clinical characteristics and predictors of mortality","volume":"98","author":"Hyldgaard","year":"2019","journal-title":"Respiration."},{"key":"10.1016\/j.autrev.2022.103056_bb0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232978","article-title":"Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease","volume":"15","author":"Avouac","year":"2020","journal-title":"Plos One"},{"key":"10.1016\/j.autrev.2022.103056_bb0230","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1056\/NEJMc070728","article-title":"Pneumocystis pneumonia associated with infliximab in Japan","volume":"357","author":"Harigai","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2022.103056_bb0235","article-title":"Adalimumab for treating rheumatoid arthritis","volume":"3","author":"Navarro-Sarabia","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2022.103056_bb0240","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10067-020-05227-9","article-title":"Non-anti-TNF biologic agents are associated with slower worsening of interstitial lung disease secondary to rheumatoid arthritis","volume":"40","author":"Mena-V\u00e1zquez","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2022.103056_bb0245","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3390\/jcm10040874","article-title":"Predictors of progression and mortality in patients with prevalent rheumatoid arthritis and interstitial lung disease: a prospective cohort study","volume":"10","author":"Mena-V\u00e1zquez","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.autrev.2022.103056_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102830","article-title":"Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: a systematic literature review","volume":"20","author":"Vicente-Rabaneda","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103056_bb0255","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.semarthrit.2016.09.011","article-title":"Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients-A longitudinal analysis","volume":"46","author":"Wunderlich","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2022.103056_bb0260","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/rheumatology\/keaa393","article-title":"The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries","volume":"60","author":"Courvoisier","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2022.103056_bb0265","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1007\/s10067-021-05854-w","article-title":"Abatacept in rheumatoid arthritis-associated interstitial lung disease: short-term outcomes and predictors of progression","volume":"40","author":"Tardella","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2022.103056_bb0270","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1093\/rheumatology\/keaa621","article-title":"Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients","volume":"59","author":"Fern\u00e1ndez-D\u00edaz","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2022.103056_bb0275","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.semarthrit.2020.08.008","article-title":"Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease","volume":"50","author":"Narv\u00e1ez","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2022.103056_bb0280","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1093\/rheumatology\/key208","article-title":"The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis","volume":"58","author":"Holroyd","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2022.103056_bb0285","article-title":"Efficacy of baricitinib in treating rheumatoid arthritis: modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting","volume":"86","author":"d\u2019Alessandro","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.autrev.2022.103056_bb0290","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.1097\/RHU.0000000000001552","article-title":"Incidence rates of interstitial lung disease events in Tofacitinib-treated rheumatoid arthritis patients: post hoc analysis from 21 clinical trials","volume":"27","author":"Citera","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.autrev.2022.103056_bb0295","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/annrheumdis-2021-eular.1236","article-title":"OP0125 Tofacitinib in rheumatoid arthritis-associated interstitial lung disease: efficacy and safety analysis from treasure real-life data","volume":"80","author":"Kalyoncu","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103056_bb0300","series-title":"AB0418 interstitial lung disease in patients with rheumatoid arthritis treated with Tofacitinib annals of the Rheumatic Diseases","first-page":"1672","volume":"78","author":"Bejarano","year":"2019"},{"key":"10.1016\/j.autrev.2022.103056_bb0305","doi-asserted-by":"crossref","first-page":"6652845","DOI":"10.1155\/2021\/6652845","article-title":"Tofacitinib for the treatment of severe interstitial lung disease related to rheumatoid arthritis","volume":"2021","author":"Vacchi","year":"2021","journal-title":"Case Rep Med"},{"key":"10.1016\/j.autrev.2022.103056_bb0310","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s40744-021-00332-w","article-title":"Baricitinib and the risk of incident interstitial lung disease: a descriptive clinical case report from clinical trials","volume":"8","author":"Salvarani","year":"2021","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.autrev.2022.103056_bb0315","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3109\/14397595.2016.1173816","article-title":"Efficacy of intensive immunosuppression in exacerbated rheumatoid arthritis-associated interstitial lung disease","volume":"27","author":"Ota","year":"2017","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2022.103056_bb0320","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.semarthrit.2021.07.008","article-title":"Intravenous cyclophosphamide in acute exacerbation of rheumatoid arthritis-related interstitial lung disease: a propensity-matched analysis using a nationwide inpatient database","volume":"51","author":"Nakamura","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2022.103056_bb0325","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"Wells","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.autrev.2022.103056_bb0330","series-title":"OP0124 effects of nintedanib in patients with progressive fibrosing interstitial lung disease associated with Rheumatoid Arthritis (RA-ILD) in the inbuild trial annals of the Rheumatic Diseases","first-page":"69","volume":"80","author":"Kelly","year":"2021"},{"key":"10.1016\/j.autrev.2022.103056_bb0335","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1093\/rheumatology\/keaa503","article-title":"Nintedanib for the treatment of refractory progressive rheumatoid arthritis-related interstitial lung disease: a real-life case series","volume":"59","author":"Narv\u00e1ez","year":"2020","journal-title":"Rheumatology (Oxford)"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722200026X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722200026X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:26:36Z","timestamp":1761600396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156899722200026X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":67,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S156899722200026X"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103056","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103056"}}